{
    "clinical_study": {
        "@rank": "33403", 
        "acronym": "HOPE-4", 
        "arm_group": [
            {
                "arm_group_label": "Intervention", 
                "arm_group_type": "Experimental", 
                "description": "Intensive CV risk detection, counselling and follow-up program by non-physician health workers (NPHW); open-label fixed-dose combination pill therapy (Polycap) in accordance with treatment algorithm; use of treatment supporters and mobile phone technology to reinforce adherence."
            }, 
            {
                "arm_group_label": "Control - Usual Care", 
                "arm_group_type": "Other", 
                "description": "Participants in control communities will be referred to usual care."
            }
        ], 
        "brief_summary": {
            "textblock": "The overall objective of the HOPE-4 study, Phases (hypertension (HT) and cardiovascular\n      disease (CVD)), is to develop and test a program for cardiovascular disease risk assessment\n      and treatment involving: (1) simple screening and treatment guidelines implemented by\n      non-physician health workers (NPHW); (2) single pill containing blood pressure and\n      cholesterol lowering drugs; and (3) family or friends and mobile phone technology to help\n      participants comply with the treatment regimen. This program has the potential to reduce\n      major cardiovascular events by 35% over 6 years, as compared to usual care."
        }, 
        "brief_title": "Heart Outcomes Prevention and Evaluation 4", 
        "completion_date": {
            "#text": "August 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hypertension", 
            "Cardiovascular Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Cardiovascular Diseases", 
                "Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study design: open-label, cluster randomized controlled trial design.\n\n      HT Phase: 50 urban and rural communities in Colombia and Malaysia will be randomized to\n      participate in an intensive cardiovascular (CV) risk detection and control program by\n      non-physician health workers (NPHW) or to care as usual for 12 months.\n\n      CVD Phase: Continuation and expansion of HT Phase to include a total of 190 urban and rural\n      communities in countries within Asia (India, Malaysia, Philippines), South America\n      (Colombia, Argentina), and Sub-Saharan Africa (South Africa, Tanzania, Rwanda) that will be\n      allocated to participate in the intensive CV risk detection and control program by NPHW or\n      to care as usual for a target of 6 years.\n\n      Communities will be randomized 1:1 with a central randomization list to either a)\n      intervention or b) control."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  >= 50 years of age\n\n          -  systolic blood pressure (SBP) 140-159 mmHg on 2 separate visits (>= 24 hours between\n             visits)\n\n          -  SBP > 160 mmHg on one visit\n\n          -  SBP < 140 mmHg but a confirmed history of HT and taking anti-HT medications\n\n          -  Reported history of diabetes, myocardial infarction (MI), cerebrovascular accident\n             (CVA), coronary artery bypass surgery or coronary angioplasty (+/- stent):\n             participant reported history of clinical diagnosis\n\n          -  Angina: participant-reported history of clinical diagnosis PLUS at least one of the\n             following:\n\n               -  Definite angina (sub-sternal chest pain that is provoked by exertion (exercise\n                  or stress) and is relieved by rest or nitroglycerin OR\n\n               -  Prescription of beta blockers, nitrates, calcium channel blockers or other\n                  antianginal drugs OR\n\n          -  Congestive heart failure (CHF): participant-reported history of clinical diagnosis\n             PLUS at least one of the following:\n\n               -  Total score of \u2265 5 points (rest dyspnea (4 points), orthopnea (4 points),\n                  paroxysmal nocturnal dyspnea (3 points), dyspnea on flat surface (2 points),\n                  dyspnea on climbing (1 point) OR\n\n               -  Prescription of furosemide (or similar loop diuretic)\n\n        General Exclusion Criteria:\n\n          -  Refusal to Consent\n\n          -  Actively involved in any study that would compromise the protocol of HOPE-4\n\n          -  Severe co-morbid condition with life expectancy < 1 year\n\n          -  Other serious condition(s) or logistic factors likely to interfere with study\n             participation or with the ability to complete the trial\n\n        Polycap Exclusion Criteria:\n\n          -  Participants with a clear contraindication or intolerance to statin, beta blocker, or\n             diuretic in the judgment of the physician\n\n          -  Participants with chronic liver disease or abnormal liver function (i.e. Alanine\n             transaminase (ALT) or aspartate aminotransferase (AST) > 3x upper limit of normal\n             (ULN))\n\n          -  Inflammatory muscle disease (such as dermatomyositis or polymyositis) or creatine\n             kinase (CK) > 3x ULN\n\n          -  Severe renal impairment (serum creatinine > 200 umol/L)\n\n          -  Potassium (K) > 5.5 mmol/L"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "9500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01826019", 
            "org_study_id": "HOPE-4"
        }, 
        "intervention": [
            {
                "arm_group_label": "Intervention", 
                "description": "In intervention communities, management plans will be developed by the NPHW for all enrolled participants.  The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate.   Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Standard and half-dose Polycap formulations will be provided to the NPHWs and supervising physicians for participant treatment.", 
                "intervention_name": "Intervention", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Control - Usual Care", 
                "description": "At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.", 
                "intervention_name": "Usual Care", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 26, 2014", 
        "link": {
            "description": "Population Health Research Institute", 
            "url": "http://www.phri.ca"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Hamilton", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "L8L 2X2"
                }, 
                "name": "Population Health Research Institute"
            }, 
            "status": "Active, not recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Heart Outcomes Prevention and Evaluation 4 (HOPE-4)", 
        "other_outcome": {
            "description": "We will collect data that will allow us to determine (i) the costs of the suggested programs (i.e. intervention package) and the costs of what is being provided currently for CVD assessment and management in the communities studied (i.e. control).", 
            "measure": "Health economic evaluations - measure/calculate the unit costs and the quantity used of each of the components of the intervention and in usual care in the participating countries.", 
            "safety_issue": "No", 
            "time_frame": "Baseline to 6 years"
        }, 
        "overall_contact": {
            "email": "tara.mccready@phri.ca", 
            "last_name": "Tara L McCready, PhD, MBA", 
            "phone": "905-527-4322", 
            "phone_ext": "40439"
        }, 
        "overall_official": [
            {
                "affiliation": "McMaster University and Hamilton Health Sciences Corp.", 
                "last_name": "Jon-David Schwalm, MD, MSc", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "McMaster University and Hamilton Health Sciences Corp.", 
                "last_name": "Salim Yusuf, MD, DPhil", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Colombia: Ministry of Health and Social Protection", 
                "Malaysia: Ministry of Health"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "The mean difference in change in systolic blood pressure (BP) between the intervention and control communities from baseline to 1 year.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 1 year (HT phase)"
            }, 
            {
                "measure": "Difference in a composite of major CV events [(CV death, MI, stroke, congestive heart failure (CHF) and CV hospitalizations (e.g. AF, unstable or new onset angina, CHF, arterial revascularization), and end-stage renal disease] from baseline to 6 years.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 Years (CVD Phase)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01826019"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The mean differences in calculated INTERHEART risk score from baseline to 1 year.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 1  year (HT Phase)"
            }, 
            {
                "measure": "The difference in the proportion of participants on antihypertensive treatment and well-controlled from baseline to 1 year.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 1 year (HT Phase)"
            }, 
            {
                "measure": "Difference in number of initiations, discontinuations, and up/down titrations of PolyCap formulations, as well as number of hospitalizations and CVD events from baseline to 1 year.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to 1 year (HT Phase)"
            }, 
            {
                "measure": "Difference in the individual components of the primary outcome from baseline to 6 years.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 Years (CVD Phase)"
            }, 
            {
                "measure": "Mean change in systolic BP, HDL, and LDL from baseline to 6 years.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 Years (CVD Phase)"
            }, 
            {
                "measure": "Mean difference in calculated lab and non-lab based INTERHEART Risk Score from baseline to 6 years.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 Years (CVD Phase)"
            }, 
            {
                "measure": "Difference in number of initiations, discontinuations, and up/down titrations of PolyCap formulations from baseline to 6 years.", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to 6 Years (CVD Phase)"
            }, 
            {
                "measure": "Mean change in systolic BP from baseline to 6 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 months(HT Phase)"
            }, 
            {
                "measure": "The mean differences in calculated non-lab based INTERHEART risk score from baseline to 6 months", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 months(HT Phase)"
            }, 
            {
                "measure": "The difference in the proportion of participants on antihypertensive treatment and well-controlled from baseline to 6 months.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 months (HT Phase)"
            }, 
            {
                "measure": "The mean change in HDL and LDL values from baseline to 1 year.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 1 year (HT Phase)"
            }, 
            {
                "measure": "Difference in number of hypertension related emergencies reported from baseline to 6 years.", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 6 Years (CVD Phase)"
            }
        ], 
        "source": "Hamilton Health Sciences Corporation", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Population Health Research Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Canadian Institutes of Health Research  (CIHR)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Grand Challenges Canada", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Global Alliance for Chronic Disease", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Cadila Pharmaceuticals Ltd", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Hamilton Health Sciences Corporation", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}